Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Starrett

Showing results (241-250 of 296) with videos related to

Pageof 30
Sort By:
Bioorganic & Medicinal Chemistry Letters|December 18, 2004
(S,E)-N-[1-(3-heteroarylphenyl)ethyl]-3-(2-fluorophenyl)acrylamides: synthesis and KCNQ2 potassium channel opener activityAlexandre L'Heureux, Alain Martel, Huan He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2019
The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung AdenocarcinomaAnna Truini, Jacqueline H Starrett, Tyler Stewart, et al.
Mbio|January 4, 2017
Merkel Cell Polyomavirus Exhibits Dominant Control of the Tumor Genome and Transcriptome in Virus-Associated Merkel Cell CarcinomaGabriel J Starrett, Christina Marcelus, Paul G Cantalupo, et al.
Journal of Medicinal Chemistry|September 11, 2024
Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and AchondroplasiaRobert L Hudkins, Eric Allen, Alexandra Balcer, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 17, 2003
An assessment of the effects of serotonin 6 (5-HT6) receptor antagonists in rodent models of learningMark D Lindner, Donald B Hodges, John B Hogan, et al.
Molecular Cancer Therapeutics|October 14, 2025
Dabogratinib (TYRA-300), an FGFR3 isoform-selective inhibitor: preclinical and initial clinical evidence of anti-tumor activityJacqueline H Starrett, Eric L Allen, Melissa Neal, et al.
Journal of Medicinal Chemistry|March 31, 2026
Structure-Based Design of a Novel Covalent 4-(1-Methylindol-3-yl)pyrimidin-2-amine Series Targeting FGFR2 Resistance MutationsRobert L Hudkins, Eric Allen, Samhita Iyer, et al.
Contemporary Clinical Trials|November 13, 2007
Design, feasibility, and acceptability of an intervention using personal digital assistant-based self-monitoring in managing type 2 diabetesMary Ann Sevick, Susan Zickmund, Mary Korytkowski, et al.
The Journal of Investigative Dermatology|October 19, 2020
Host-Pathogen Interactions in Human Polyomavirus 7‒Associated Pruritic Skin EruptionRachel K Rosenstein, Diana V Pastrana, Gabriel J Starrett, et al.
Science (New York, N.Y.)|August 12, 2000
Ecology. The value of nature and the nature of valueG C Daily, T Söderqvist, S Aniyar, et al.
Pageof 30

Showing results (241-250 of 296) with videos related to

Sort By:
Pageof 30
Bioorganic & Medicinal Chemistry Letters|December 18, 2004
(S,E)-N-[1-(3-heteroarylphenyl)ethyl]-3-(2-fluorophenyl)acrylamides: synthesis and KCNQ2 potassium channel opener activityAlexandre L'Heureux, Alain Martel, Huan He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2019
The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung AdenocarcinomaAnna Truini, Jacqueline H Starrett, Tyler Stewart, et al.
Mbio|January 4, 2017
Merkel Cell Polyomavirus Exhibits Dominant Control of the Tumor Genome and Transcriptome in Virus-Associated Merkel Cell CarcinomaGabriel J Starrett, Christina Marcelus, Paul G Cantalupo, et al.
Journal of Medicinal Chemistry|September 11, 2024
Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and AchondroplasiaRobert L Hudkins, Eric Allen, Alexandra Balcer, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 17, 2003
An assessment of the effects of serotonin 6 (5-HT6) receptor antagonists in rodent models of learningMark D Lindner, Donald B Hodges, John B Hogan, et al.
Molecular Cancer Therapeutics|October 14, 2025
Dabogratinib (TYRA-300), an FGFR3 isoform-selective inhibitor: preclinical and initial clinical evidence of anti-tumor activityJacqueline H Starrett, Eric L Allen, Melissa Neal, et al.
Journal of Medicinal Chemistry|March 31, 2026
Structure-Based Design of a Novel Covalent 4-(1-Methylindol-3-yl)pyrimidin-2-amine Series Targeting FGFR2 Resistance MutationsRobert L Hudkins, Eric Allen, Samhita Iyer, et al.
Contemporary Clinical Trials|November 13, 2007
Design, feasibility, and acceptability of an intervention using personal digital assistant-based self-monitoring in managing type 2 diabetesMary Ann Sevick, Susan Zickmund, Mary Korytkowski, et al.
The Journal of Investigative Dermatology|October 19, 2020
Host-Pathogen Interactions in Human Polyomavirus 7‒Associated Pruritic Skin EruptionRachel K Rosenstein, Diana V Pastrana, Gabriel J Starrett, et al.
Science (New York, N.Y.)|August 12, 2000
Ecology. The value of nature and the nature of valueG C Daily, T Söderqvist, S Aniyar, et al.
Pageof 30